TABLE 2.

Effect of removing anti-OspA, anti-OspC, or anti-OspC7 antibodies on borreliacidal activity in immune sera^a collected 7 days after vaccination and boost with the bivalent (isolate S-1-10 and 50772) bacterin

Serum sample	Borreliacidal antibody titerb detected by using:
	B. burgdorferi S-1-10				B. burgdorferi 50772
	Untreated	rOspA adsorbed	rOspC adsorbed	rOspC7 adsorbed	Untreated	rOspA adsorbed	rOspC adsorbed	rOspC7 adsorbed
OspA controlc	2,560	NDd	2,560	2,560	NTe	NT	NT	NT
OspC controlc	NT	NT	NT	NT	2,560	2,560	ND	ND
1	20,480	160	20,480	NT	10,240	10,240	1,280	2,560
2	10,240	160	10,240	NT	10,240	10,240	640	5,120
3	10,240	ND	10,240	NT	10,240	10,240	640	2,560
4	5,120	ND	5,120	NT	5,120	5,120	640	1,280
5	5,120	80	5,120	NT	5,120	5,120	640	1,280

^aFive immune serum samples were tested.

^bReciprocal dilution. rOspA adsorbed, anti-OspA antibodies removed; rOspC adsorbed, anti-OspC antibodies removed; rOspC7 adsorbed, anti-OspC7 antibodies removed.

^cHuman Lyme disease serum containing anti-OspA or anti-OspC borreliacidal antibodies.

^dND, none detected.

^eNT, not tested.